DERMATA THERAPEUTICS INC
DRMANASDAQTrading Snapshot
- Day Range
- โ
- 52-Week Range
- $0.50 โ $4.66
- Volume (shares)
- โ
- Avg Volume (shares)
- โ
- Shares Outstanding
- 5.0M
- Next Earnings
- โ
Fundamentals Snapshot
- Annual Revenue
- โ
- Last Q Revenue
- $74,137
- P/E Ratio
- โ
- P/S Ratio
- โ
- EPS (TTM)
- $-4.51
- Dividend Yield
- โ
DERMATA THERAPEUTICS INC
DRMAFinancial history unavailable.
About DERMATA THERAPEUTICS INC
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.